These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 18596737)

  • 41. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia.
    Mangaonkar AA; Hoversten KP; Gangat N
    Expert Rev Hematol; 2018 Mar; 11(3):247-252. PubMed ID: 29313725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [State-of-the-art management for essential thrombocythemia and polycythemia vera].
    Sugimoto Y
    Rinsho Ketsueki; 2021; 62(8):1050-1059. PubMed ID: 34497191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
    Reikvam H; Tiu RV
    Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
    Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modern treatment strategies in polycythemia vera.
    Gilbert HS
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):26-9. PubMed ID: 12682879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
    Reiter A; Harrison C
    Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
    Tefferi A; Vainchenker W
    J Clin Oncol; 2011 Feb; 29(5):573-82. PubMed ID: 21220604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A clinical update in polycythemia vera and essential thrombocythemia.
    Tefferi A; Solberg LA; Silverstein MN
    Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Ricksten A; Palmqvist L; Johansson P; Andreasson B
    Haematologica; 2008 Aug; 93(8):1260-1. PubMed ID: 18519514
    [No Abstract]   [Full Text] [Related]  

  • 56. [Recent advances in polycythemia vera treatment].
    Edahiro Y
    Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
    Vannucchi AM
    Intern Emerg Med; 2010 Jun; 5(3):177-84. PubMed ID: 19789961
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drugs in essential thrombocythemia and polycythemia vera.
    Tefferi A; Elliott MA; Solberg LA; Silverstein MN
    Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence-based management of polycythemia vera.
    Barbui T; Finazzi G
    Best Pract Res Clin Haematol; 2006; 19(3):483-93. PubMed ID: 16781485
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.
    Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2020 Nov; 13(11):1189-1199. PubMed ID: 33076714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.